Mads Daugaard

Mads Daugaard

Company: Rakovina Therapeutics

Job title: President & Chief Scientific Officer


Exploring a Novel Dual PARP-HDAC Inhibitor for the Treatment of Ewing Sarcoma 9:00 am

kt-3000 series compounds exhibit dual PARP1/2 and HDAC inhibitor activity Co-inhibition of PARP1/2 and HDACs amplifies DNA damage and cytotoxicity Ewing sarcoma cells are highly sensitive to combined PARP and HDAC inhibitionRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.